Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.
“The big advantage of the Tmod technology is that it's a way to selectively target cancer cells. And again, this approach is so unique in the way that in the same construct, you are able to modulate this expression: you're able to have a blocker and you are able to have an activator to use depending on what the cancer cells express.”
Data on the observational BASECAMP-1 study and preclinical data on Tmod chimeric antigen receptor (CAR) T-cell therapies were presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 10-14, 2021, by Julian Molina, MD, PhD, professor, oncology, Mayo Clinic.
Mayo Clinic and A2 Biotherapeutics are partnering to develop mesothelin (MSLN) and carcinoembryonic antigen (CEA)-targeted TmodCAR T-cell therapies. Preclinical data has demonstrated the technology’s robust protective effect on surrogate normal human cells in vitro, even in mixed-cell populations, while also yielding a robust cytotoxic effect on tumor cells in xenograft models.
The BASECAMP-1 study is being conducted to identify patients with relapsed solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH) as a future target for Tmod cell therapy.
GeneTherapyLive spoke with Molina to learn more about Tmod technology and how it compares to other T-cell therapies. He discussed advantages of the technology in solid tumors.
